市场调查报告书
商品编码
1262695
呼吸系统疾病检测市场——按检测类型、最终用途和预测,2023-2032 年Respiratory Disease Testing Market - By Test Type, By Application By End-use & Forecast, 2023 - 2032 |
预计到 2032 年,呼吸系统疾病检测市场的收入将显着增长。
这是由于欠发达经济体中吸烟者数量的增加,以及对粉尘的高度暴露。 据世界卫生组织统计,中国约有3亿烟民,约占世界烟民总数的三分之一。 吸烟者数量的显着增加增加了这些经济体的呼吸道疾病负担,进一步增加了对呼吸道疾病检测的需求。
从检查项目来看,由于影像技术的进步,预计到2032年,影像检查领域的呼吸系统疾病检查市场将呈现显着增长。 事实上,计算机断层扫描的最新进展使 COPD 的结构异常和解剖定位可视化成为可能。
此外,许多行业参与者都在关注新产品创新,这也将有利于该细分市场的增长。 例如,2022 年 11 月,成像技术领域的全球领导者 CAREStream Health 宣布了一款新的数字 X 射线检测器,该检测器有助于获取更好的解剖图像以改善临床结果。。
根据应用,慢性阻塞性肺疾病 (COPD) 呼吸系统疾病检测行业预计到 2032 年估值将超过 100 亿美元。 空气污染水平上升、饮食不健康和人口老龄化导致慢性阻塞性肺病激增,增加了对呼吸系统疾病检测的需求。 根据 CDC 的数据,COPD 影响着超过 1500 万美国人,每年有超过 150,000 名美国人死于该病。
从销售渠道来看,诊所领域的呼吸系统疾病检测行业预计从 2023 年到 2032 年将以相当大的复合年增长率增长。 由于对先进的、具有成本效益的呼吸检测设备的偏好日益增加,诊所的患者人流量增加了。 此外,这些设施拥有大量熟练的医务人员,非常适合诊断和治疗呼吸系统疾病。
按地区划分,在 Siemens Healthineers、Koninklijke Philips N.V 等不断推出新产品的推动下,2023 年至 2032 年欧洲呼吸系统疾病检测市场的复合年增长率预计将超过 6.5%。致力于创新的主要行业巨头。 事实上,在 2022 年 7 月,德国医疗设备製造商西门子医疗宣布推出 Mobilett Impact,这是一种移动 X 射线系统,可以在患者床边进行肺部检查。
Respiratory disease testing market is anticipated to register substantial revenue gains through 2032, owing to high exposure to dust particles coupled with the growing number of cigarette smokers in underdeveloped and developing economies. As per WHO, there are nearly 300 million smokers in China, which accounts for around one-third of the total number of smokers globally. The remarkable rise in the number of smokers has increased the burden of respiratory diseases in these economies, further augmenting the need for respiratory disease testing.
On the basis of the test, the respiratory disease testing market from the imaging tests segment is expected to garner significant gains through 2032, owing to advancements in imaging technologies. In fact, recent developments in computed tomography imaging have made it possible to visualize structural derangements and anatomic localization of COPD.
Moreover, many industry players are putting consolidated efforts into new product innovations, which will also favor segment growth. For instance, in November 2022, CAREstream Health, a global leader in imaging technology, unveiled new digital x-ay detectors which will help better acquire images of anatomical structures for enhanced clinical outcomes.
In terms of application, the respiratory disease testing industry from the chronic obstructive pulmonary disease (COPD) segment is poised to record a valuation of over USD 10 billion by 2032. The surging occurrence of COPD owing to rising air pollution levels, unhealthy diets, the growing geriatric population, and others has bolstered the need for respiratory disease testing. As per CDC, COPD affects over 15 million Americans and over 150,000 Americans die of the disease every year.
Based on the distribution channel, the respiratory disease testing industry from the clinics segment is poised to grow at a considerable CAGR from 2023 to 2032. The rising preference for cost-effective and advanced respiratory testing equipment has increased patient footfall in clinics. Moreover, these facilities also have a high availability of skilled healthcare professionals, making them a preferred healthcare provider for the diagnosis and treatment of respiratory disorders.
Regionally speaking, Europe respiratory disease testing market is slated to grow at over 6.5% CAGR from 2023 to 2032, owing to the strong presence of key industry giants such as Siemens Healthineers, Koninklijke Philips N.V., among others who are constantly indulged in new product innovations. In fact, in July 2022, Siemens Healthineers, a German medical device manufacturer, announced the launch of Mobilett Impact, a mobile X-ray system that can perform lung examinations at a patient's bedside.